CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas

Simona Bortolotto, Loredana Chiadò-Piat, Paola Cavalla, Ivana Bosone, Adriano Chiò, Alessandro Mauro, Davide Schiffer

Research output: Contribution to journalArticlepeer-review


The cell-cycle regulator p16 inhibits the complex cdk4-cyclin DI and controls GI-S transition. In human tumors, p16 inactivation is often accomplished by homozygous deletion (HD) of its encoding gene, CDKN2A. Methylation of the 5' CpG island promoter has been proposed as an alternative mechanism of inactivation. Expression of p16, CDKN2A Hd and 5' CDKN2A CpG island methylation was studied in 25 oligodendrogliomas by immunohistochemistry and PCR amplification. Ten oligodendrogliomas were p16-immunonegative, and CDKN2A HD was determined in 8 of these cases. In the 2 immunonegative cases without HD, no CpG island methylation was found. The absence of CpG island methyl ation in the p16-immunonegative cases without HD suggests either non-genetic regulation of p16 or different genetic changes. CDKN2A HD did not correlate with histological grading (p = n.s.); however, it showed a correlation with survival (p = 0.03), supporting an important role of CDKN2A in the prognosis of oligodendrogliomas. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)554-557
Number of pages4
JournalInternational Journal of Cancer
Issue number4
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas'. Together they form a unique fingerprint.

Cite this